New Liquid Biopsy Approach Shows Promise in Early Breast Cancer Detection and Recurrence Prediction
Researchers have developed an experimental blood test leveraging epigenetic mapping and AI to accurately detect early-stage breast cancer and predict recurrence risks.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- New blood test analyzes epigenetic tags rather than genetic mutations to spot early breast cancer.
- AI models trained on patient data achieved 95% accuracy in detecting early-stage tumors.
- The method also outperformed conventional tissue biopsies in predicting patient recurrence risks.
Liquid biopsies have long been pursued as a minimally invasive method to spot cancer early, customize therapies, and foresee relapses. However, traditional approaches often struggle with early detection due to the extreme scarcity of genetic cancer traces in the bloodstream and the risk of false positives. A collaborative team from the Hebrew University of Jerusalem and the Weizmann Institute of Science, alongside clinicians at Kaplan Medical Center, has introduced a novel blood test that targets epigenetic markers rather than purely genetic mutations.
Instead of examining DNA sequences alone, the investigators focused on epigenetic tags—regulatory bookmarks that dictate how genes are expressed within cells. By collaborating with the Mayo Clinic in Florida, the researchers evaluated blood samples from 77 breast cancer patients tracked for over five years and 30 healthy individuals. Utilizing single-molecule microscopy and specialized artificial intelligence algorithms, the system achieved 95 percent accuracy in identifying early-stage breast cancer when tumors were confined and measured two centimeters or smaller.
While these findings are promising, the study remains an early-stage clinical investigation relying on a relatively small cohort. Observational findings of this nature require extensive validation in larger, diverse populations before broad clinical implementation can be considered. The research suggests a potential pathway forward, but limitations in sample size mean it is not yet a diagnostic standard.
What to know: The experimental blood test examines epigenetic tags on nucleosomes released into the blood to spot early breast cancer and estimate recurrence likelihood. Readers should consult qualified healthcare professionals for individual medical guidance and standard screening decisions.
Source Medical Xpress — medicalxpress.com/news/2026-11-experimental-blood-early-breast-cancer.h… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.